MedTrace Logo

Cross Validation of Body Composition Measurement

NCT06453564 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-03-30

No results posted yet for this study

Summary

Obesity, as a chronic disease, has emerged as one of the most pressing health concerns in the 21st century. According to statistics, over 2.1 billion individuals worldwide are affected by overweight or obesity. It is worth noting that obesity ranks fifth among the leading causes of mortality globally. Body fat percentage (fat%) serves as an accurate measure for evaluating body fat content, which can be further categorized into subcutaneous fat, intra-abdominal fat, and intra-organ fat. Subcutaneous fat primarily functions in heat preservation and energy storage while intra-abdominal fat plays a crucial role in safeguarding internal organs from harm. Visceral fat deposition mainly occurs due to intracellular lipid degeneration within organ cells. Extensive research has demonstrated significant variations in metabolic indications and risks associated with different types of fats across various body regions. Therefore, precise segmentation and quantification of overall body fat composition and its distribution hold immense significance for studying individual obesity characteristics, predicting health outcomes, facilitating clinical diagnosis, and devising effective treatment strategies. However, it should be noted that current instruments used for measuring body composition exhibit varying levels of accuracy. Henceforth, this study aims to cross-validate several commonly employed body composition analyzers including DXA (Dual-energy X-ray Absorptiometry), BIA (Bioelectrical Impedance Analysis), BODPOD (Air Displacement Plethysmography), MRI (Magnetic Resonance Imaging), deuterium dilution technique, and 3D laser scanning techniques to assess their agreement and discrepancies when measuring different aspects of body composition.

Conditions

  • Body Composition

Sponsors & Collaborators

  • John R. Speakman

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-19
Primary Completion
2026-07-19
Completion
2026-07-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06453564 on ClinicalTrials.gov